Covered recipient · General Payments record
SHAHRAM ABRISHAMY
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$5,309.76
- Reported across 158 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $767.95 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $274.10 | 2 |
| ABBVIE INC. | $193.10 | 9 |
| Regeneron Healthcare Solutions, Inc. | $120.01 | 1 |
| MERZ NORTH AMERICA, INC. | $102.06 | 3 |
| REVANCE THERAPEUTICS, INC. | $56.26 | 2 |
| Galderma Laboratories, L.P. | $22.42 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.98 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169780 | CMS |
| ABBVIE INC. | $30.07 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169782 | CMS |
| ABBVIE INC. | $24.53 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169784 | CMS |
| ABBVIE INC. | $18.27 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169786 | CMS |
| ABBVIE INC. | $32.16 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169788 | CMS |
| ABBVIE INC. | $21.79 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169790 | CMS |
| ABBVIE INC. | $29.56 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169792 | CMS |
| ABBVIE INC. | $2.41 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169794 | CMS |
| ABBVIE INC. | $19.33 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103169796 | CMS |
| Amgen Inc. | $124.10 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117488526 | CMS |
| Amgen Inc. | $150.00 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117488528 | CMS |
| Galderma Laboratories, L.P. | $22.42 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145282405 | CMS |
| MERZ NORTH AMERICA, INC. | $27.63 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146375028 | CMS |
| MERZ NORTH AMERICA, INC. | $29.80 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146375024 | CMS |
| MERZ NORTH AMERICA, INC. | $44.63 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146375026 | CMS |
| Regeneron Healthcare Solutions, Inc. | $120.01 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113993901 | CMS |
| REVANCE THERAPEUTICS, INC. | $27.53 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147911110 | CMS |
| REVANCE THERAPEUTICS, INC. | $28.73 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147911112 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.